BR0314338A - Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma - Google Patents

Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma

Info

Publication number
BR0314338A
BR0314338A BR0314338-4A BR0314338A BR0314338A BR 0314338 A BR0314338 A BR 0314338A BR 0314338 A BR0314338 A BR 0314338A BR 0314338 A BR0314338 A BR 0314338A
Authority
BR
Brazil
Prior art keywords
solid oral
oral medicine
dysuria
treatment
same
Prior art date
Application number
BR0314338-4A
Other languages
English (en)
Inventor
Eiji Tsuru
Michio Toda
Kazuma Hirata
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31973150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR0314338A publication Critical patent/BR0314338A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

"SUBSTâNCIA CRISTALINA PARA MEDICAMENTO ORAL SóLIDO E MEDICAMENTO ORAL SóLIDO PARA O TRATAMENTO DE DISúRIA CONTENDO A MESMA". Uma substância cristalina para medicamento oral sólido que compreende um composto de indolina (KMD-3213), e que exerce uma atividade bloqueadora do receptor de <244>~ 1~-adrenalina, é útil como um agente terapêutico para disúria e é representado pela fórmula: (I) em que, no padrão de difração de raios X de pó, o composto é caracterizado por picos principais de 5,5<198> <sym> 0,2<198>, 6,1<198> <sym> 0,2<198>, 9,8<198> <sym> 0,2<198>, 11,1 <sym> 0,2<198>, 12,2<198> <sym> 0,2<198>, 16,4<198> <sym> 0,2<sym>, 19,7<198> <sym> 0,2<198> e 20,0<198> <sym> 0,2<198> como 2 <sym>. é ainda proposto um medicamento oral sólido para o tratamento de disúria contendo a substância cristalina como um ingrediente ativo.
BR0314338-4A 2002-09-06 2003-09-05 Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma BR0314338A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002262157 2002-09-06
PCT/JP2003/011345 WO2004022538A1 (ja) 2002-09-06 2003-09-05 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬

Publications (1)

Publication Number Publication Date
BR0314338A true BR0314338A (pt) 2005-07-05

Family

ID=31973150

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314338-4A BR0314338A (pt) 2002-09-06 2003-09-05 Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma

Country Status (24)

Country Link
US (1) US20060142374A1 (pt)
EP (1) EP1541554B1 (pt)
JP (1) JP4532274B2 (pt)
KR (1) KR100670592B1 (pt)
CN (1) CN1321111C (pt)
AT (1) ATE416159T1 (pt)
AU (1) AU2003264385B2 (pt)
BR (1) BR0314338A (pt)
CA (1) CA2496780C (pt)
DE (1) DE60325074D1 (pt)
ES (1) ES2316858T3 (pt)
HK (1) HK1084396A1 (pt)
HR (1) HRP20050214B1 (pt)
IL (1) IL167168A (pt)
IS (1) IS2640B (pt)
MX (1) MXPA05002549A (pt)
NO (2) NO329855B1 (pt)
NZ (1) NZ538598A (pt)
PL (1) PL375701A1 (pt)
RU (1) RU2347774C2 (pt)
TW (1) TW200407126A (pt)
UA (1) UA78854C2 (pt)
WO (1) WO2004022538A1 (pt)
ZA (1) ZA200501884B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4633469B2 (ja) * 2002-12-16 2011-02-16 キッセイ薬品工業株式会社 経口固形医薬
ES2436608T3 (es) * 2004-03-05 2014-01-03 Kissei Pharmaceutical Co., Ltd. Composición medicinal para la prevención o el tratamiento de la vejiga hiperactiva asociada a un trastorno nervioso
JPWO2006038611A1 (ja) * 2004-10-05 2008-05-15 キッセイ薬品工業株式会社 下部尿路閉塞疾患に伴う蓄尿障害の予防及び／又は治療剤
SI1806136T1 (sl) * 2004-10-06 2012-03-30 Kissei Pharmaceutical Medicinski sestavek za preprečevanje prehoda na operativno zdravljenje prostatične hipertrofije
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2672414A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries Ltd. Crystalline solid rasagiline base
US8013007B2 (en) * 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
MX2009009230A (es) * 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102010359B (zh) * 2010-09-10 2013-01-23 北京阳光诺和药物研究有限公司 β晶型西洛多辛的制备方法
WO2012077138A1 (en) * 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
SI2474529T1 (sl) 2010-12-23 2014-12-31 Sandoz Ag Kristalne oblike aktivne farmacevtske učinkovine
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) * 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
WO2014157137A1 (ja) * 2013-03-26 2014-10-02 キッセイ薬品工業株式会社 シロドシンの苦味をマスキングした経口投与製剤
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
WO2015015512A2 (en) * 2013-07-29 2015-02-05 Ind-Swift Laboratories Limited Process for the preparation of silodosin and its gamma form
JP2015117192A (ja) * 2013-12-17 2015-06-25 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
WO2015119057A1 (ja) 2014-02-06 2015-08-13 宇部興産株式会社 インドリン化合物の製造方法
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016147811A (ja) * 2015-02-10 2016-08-18 ダイト株式会社 シロドシンγ型結晶の製造方法
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
KR101733084B1 (ko) 2016-07-27 2017-05-08 (주)다산메디켐 실로도신의 결정형의 제조방법
EP3354283B1 (en) 2017-06-20 2019-08-07 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical capsule composition comprising silodosin
JP2018035199A (ja) * 2017-12-07 2018-03-08 東和薬品株式会社 シロドシンγ型結晶及びその製造方法
CN107903201B (zh) * 2017-12-27 2020-09-25 浙江天宇药业股份有限公司 一种β晶型西洛多辛的制备方法
CN111410626B (zh) * 2019-01-04 2022-11-04 上海汇伦医药股份有限公司 赛洛多辛α-晶型的制备方法
CN109824569B (zh) * 2019-04-04 2022-09-20 重庆医药高等专科学校 一种西罗多辛晶型i及其制备方法
WO2020237643A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛α-晶型的制备方法
CN114601826A (zh) * 2022-03-31 2022-06-10 乐泰药业有限公司 一种用于治疗前列腺增生的药物制剂及其制备方法和质量检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600675B1 (en) * 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
JP3331048B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドール誘導体
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
AU3011299A (en) * 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP4324266B2 (ja) * 1999-02-26 2009-09-02 キッセイ薬品工業株式会社 α１Ａアドレナリン受容体の変異体、当該変異体を用いた測定方法及び前立腺肥大に伴う排尿困難症治療剤
JP4921646B2 (ja) * 2001-03-08 2012-04-25 キッセイ薬品工業株式会社 １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法
CN101048376B (zh) * 2004-10-27 2011-03-23 橘生药品工业株式会社 二氢吲哚化合物及其生产方法

Also Published As

Publication number Publication date
ES2316858T3 (es) 2009-04-16
PL375701A1 (en) 2005-12-12
JP4532274B2 (ja) 2010-08-25
KR20050057181A (ko) 2005-06-16
TWI305148B (pt) 2009-01-11
NO20051709L (no) 2005-06-06
NO329855B1 (no) 2011-01-10
CN1694867A (zh) 2005-11-09
IS2640B (is) 2010-06-15
KR100670592B1 (ko) 2007-01-17
ATE416159T1 (de) 2008-12-15
HRP20050214B1 (hr) 2013-09-30
ZA200501884B (en) 2006-05-31
EP1541554B1 (en) 2008-12-03
NZ538598A (en) 2007-08-31
IL167168A (en) 2010-11-30
RU2005109930A (ru) 2006-01-20
HK1084396A1 (en) 2006-07-28
IS7785A (is) 2005-04-05
JPWO2004022538A1 (ja) 2005-12-22
WO2004022538A1 (ja) 2004-03-18
UA78854C2 (en) 2007-04-25
NO2011011I1 (no) 2011-07-25
HRP20050214A2 (en) 2006-05-31
CA2496780C (en) 2011-03-15
MXPA05002549A (es) 2005-06-03
EP1541554A4 (en) 2006-11-08
EP1541554A1 (en) 2005-06-15
DE60325074D1 (de) 2009-01-15
NO2011011I2 (pt) 2012-10-01
TW200407126A (en) 2004-05-16
AU2003264385A1 (en) 2004-03-29
RU2347774C2 (ru) 2009-02-27
AU2003264385B2 (en) 2009-12-17
CA2496780A1 (en) 2004-03-18
CN1321111C (zh) 2007-06-13
US20060142374A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BR0314338A (pt) Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
CA2476800A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
NO20020968L (no) Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
RU2008143362A (ru) Сокристаллическая форма производного с-гликозида c l-пролином
SE9901573D0 (sv) New compounds
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
MY121170A (en) Polymorphic salt of an anti-migrain drug.
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom
SE9901572D0 (sv) New compounds
BR9917315A (pt) Composições medicinais para liberação imediata para uso oral
NO20013601L (no) Nye morfolinobenzamidsalter
NO20045223L (no) Orto-substituerte benzosyrederivater for behandling av insulinresistens
NO20013480L (no) Legemiddel for torr hud
SE0103272D0 (sv) Chemical compounds
DE60106246D1 (de) Malto-oligosaccharide und deren verwendung
TH28860A (th) สารประกอบชนิดใหม่
UY27855A1 (es) Compuestos quimicos
NO20080947L (no) Terapeutisk middel for hypertensjon
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения
TH75889A (pt)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]